Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | USP2 | O75604 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | RECQL | P46063 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 4/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetracycline SCHEMBL4932253 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL12856676 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL12356690 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Epitetracycline SCHEMBL19771301 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL2614976 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL16302914 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL13223984 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL6666071 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL21900130 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL12247641 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1384479-A1 | Preventing or reducing photosensitivity and/or phototoxicity reactions to antiinfective medications | G.D. SEARLE & CO. (US) | 2004-01-28 | — | — | EP | claimed |
| EP-0741570-B1 | PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO ANTIINFECTIVE MEDICATIONS | SEARLE & CO (US) | 2003-05-07 | — | — | EP | claimed |
| US-6172069-B1 | CONTROLLING TIME OF ADMINISTERING | G. D. SEARLE & COMPANY | 2001-01-09 | — | — | US | claimed |
| US-20080139545-A1 | FORMULATION TO TREAT EAR INFECTION | CHOE WON-TAEK | 2008-06-12 | — | — | US | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| EP-1384479-A1 | Preventing or reducing photosensitivity and/or phototoxicity reactions to antiinfective medications | G.D. SEARLE & CO. (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-0741570-B1 | PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO ANTIINFECTIVE MEDICATIONS | SEARLE & CO (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
| US-5668134-A | LOMEFLOXACIN HYDROCHLORIDE | G. D. SEARLE & CO. (US) | 1997-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | MEN1 1965/4885KMT2A 4258/4885TDP1 3879/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | MEN1 437/4885KMT2A 572/4885TDP1 3850/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | MEN1 54/4885KMT2A 4042/4885TDP1 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.